​

     OncoNanoLab is an interdisciplinary research group bridging cutting-edge nanomedicine with clinical oncology, focused on tackling some of the most pressing challenges in cancer diagnosis, treatment, and survivorship. We engineer smart, bioresponsive nanomaterials for precision therapy, immunomodulation, and image-guided interventions, integrating AI-driven design and translational frameworks to accelerate clinical impact.

     Our work spans from fundamental cancer biology, including tumor heterogeneity, drug resistance, and metastasis, to real-world applications, such as health equity, patient quality of life, and global cancer burden analyses. Through collaboration with clinicians, public health experts, and global science consortia, we aim to develop personalized and accessible cancer solutions for diverse populations.

Backed by over 150 publications in leading journals (Nature, The Lancet, Nature Materials, The Lancet Oncology, Nature Nanotechnology, JAMA Oncology, Advanced Materials, JACS, Matter, PNAS, Trends in Cancer, among others), OncoNanoLab is driven by innovation, translation, and a deep commitment to advancing both science and society.​

​

     Our research, conducted at NOVA Medical School and Universidade NOVA de Lisboa, is in line with Sustainable Development Goals (SDG) from United Nations, particularly with Goal 3 of Agenda 2030 to ensure healthy lives and promote well-being for all at all ages, as well as aligned with Goal 9 promoting inclusive and sustainable industrialization and foster innovation.

​